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ABSTRACT
Carcinosarcoma of the prostate is a rare neoplasm with
malignant epithelial and mesenchymal components.
Herein, we report the case of a patient who underwent
multiple transurethral resections of the prostate showing
adenocarcinoma initially then carcinosarcoma. He under-
went a robotic-assisted laparoscopic cystoprostatectomy,
bilateral pelvic lymph node dissection, and ileal conduit
urinary diversion and was discharged on postoperative
day 7. Carcinosarcoma is discussed as an extremely rare
malignancy of the prostate, with less than 50 cases re-
ported in the literature. Robotic-assisted radical cystopros-
tatectomy is also discussed as a new procedure in mini-
mally invasive surgery and as the first reported use for
prostatic carcinosarcoma.
Key Words: Prostate, Robotic surgery, Carcinosarcoma,
Laparoscopy.
INTRODUCTION
Carcinosarcoma of the prostate gland is a rare malignancy
characterized by an admixture of malignant epithelial and
mesenchymal components. Because it was presumed that
the origin of these tumors was a carcinoma with varying
degrees of differentiation including a sarcomatoid pattern,
these tumors were first called “sarcomatoid carcinoma.”1
The contemporary classification, carcinosarcoma, is a
more accurate description of this tumor because it com-
prises components of both adenocarcinoma and sarcoma.
In contrast, a sarcomatoid carcinoma would apply to pure
spindle cell tumors with epithelial differentiation.
The incidence of carcinosarcoma is estimated to be less
than 0.1%,2 with only 50 documented cases in the English
literature. Of interest, 48% to 55% of patients diagnosed
with prostatic carcinosarcoma have a history of adenocar-
cinoma of the prostate.3 The objectives of this paper are to
report a case of carcinosarcoma of the prostate resected
by robotic-assisted radical cystoprostatectomy as well as dis-
cuss this new minimally invasive procedure as the first re-
ported use for prostatic adenocarcinoma.
METHODS
A 73-year-old man who had undergone transurethral nee-
dle ablation of the prostate in the past underwent trans-
urethral resection of the prostate (TURP) for obstructive
voiding symptoms refractory to alpha blockade. The pa-
thology was notable for 2 foci of Gleason 336 adeno-
carcinoma and several foci of high-grade prostatic intra-
epithelial neoplasia. The patient elected observation but
developed recurrent obstructive voiding symptoms within
6 months. A cystoscopy at that time demonstrated exten-
sive prostatic regrowth, and the patient underwent a sec-
ond TURP. The pathology from the second TURP revealed
adenocarcinoma with Gleason 549 involving approx-
imately half the prostatic chips.
At this point, androgen ablation therapy was initiated and
a PSA nadir of 0.3ng/mL was achieved. One year later, a
third TURP was required for recurrent urinary retention. At
this time, the pathology demonstrated carcinosarcoma. A
metastatic evaluation including whole body PET CT scan
and MRI of the head were negative and PSA was 0.1
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SCIENTIFIC PAPERng/mL. At this point, the patient was referred to our
institution for definitive management.
RESULTS
After cystoscopic examination that demonstrated exten-
sion of the tumor into the bladder neck, a robotic-assisted
laparoscopic cystoprostatectomy, bilateral pelvic lymph
node dissection, and ileal conduit urinary diversion were
performed. Operative time was 6 hours. Estimated blood
loss was 250 mL, and 2 units of packed red blood cells
were given intraoperatively for a hemoglobin of 9.6mg/dL
and a hematocrit of 26.8% compared with preoperative
values of 13.3 mg/dL and hematocrit of 38.1%. Posttrans-
fusion hemoglobin was 11.4 mg/dL and hematocrit was
30.7%. The patient had an unremarkable postoperative
course and was discharged from the hospital on postop-
erative day 7. He was fully recovered 3 weeks following
the procedure and traveled to Mexico on a family vaca-
tion.
The gross pathology demonstrated tumor protruding into,
but not invading, the bladder (Figure 1). Microscopic
examination revealed leiomyosarcoma and a separate fo-
cus (1% of specimen) of adenocarcinoma, Gleason grade
4 (Figure 2). The pathologic stage was T3 N0, with
extracapsular extension. Surgical margins were negative.
The patient is currently undergoing adjuvant external
beam radiation.
DISCUSSION
Carcinosarcoma of the prostate was first reported in
1967.4,5 Multiple theories exist about the development of
prostatic carcinosarcoma. One postulation is that both
carcinoma and sarcoma develop simultaneously from dif-
ferent areas of the prostate. A second theory is dual dif-
ferentiation from an immature totipotential cell. Other
possibilities include transformation of adenosarcoma into
sarcoma or transformation of sarcoma into adenosarcarci-
noma. Finally, tumor dedifferentiation due to radiation or
hormone therapy has been proposed.2,6
Postradiation sarcoma (PRS) of the prostate was described
by Canfield et al7 in 2001. They distinguished between
carcinosarcoma and PRS of the prostate by histology and
latency period. Carcinosarcoma was defined as prostatic
cancer containing poorly differentiated adenocarcinoma
mixed with sarcomatous elements, sometimes associated
with a history of radiation or hormone ablation, less than
10 years before diagnosis. Pure PRS of the prostate was
described as sarcoma alone, in a previously irradiated
patient, 25 years after the original neoplasm (one testicu-
lar cancer and one prostate cancer, histology not re-
ported). The study concluded that with only 2 cases of
PRS of the prostate reported, the entity was extremely
rare. Considering this extremely small number and the fact
that only a fraction (14% to 21%)3 of patients with carci-
nosarcoma have a history of radiation therapy, radiation
Figure 1. Gross cystoprostatectomy specimen. Pathology dem-
onstrated prostatic carcinosarcoma.
Figure 2. Hematoxylin and Eosin (H&E) stain showing spindle
cells and adenocarcinoma.
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nosarcoma.
Similarly, as the number of patients treated by androgen
deprivation therapy greatly exceeds the number of cases
of carcinoma arising in patients with previous androgen
deprivation therapy, hormone therapy is unlikely to have
a role in development of carcinosarcoma. In a series of 21
patients with carcinosarcoma by Dundore et al3 in 1995,
only 5 of 21 patients (24%) had a history of androgen
deprivation therapy.
Biochemically, prostatic carcinosarcoma usually have a
PSA level within normal ranges.6 This may be explained
by the undifferentiated nature of the sarcoma cells, hence
the inability to produce PSA.8
Histologically, the epithelial portion is adenosarcoma with
a variable sarcoma component. A review of 41 cases2
demonstrated osteosarcoma to be the most common
(50%), followed by chondrosarcoma (33%), leiomyosar-
coma (17%), rhabdosarcoma (12%), malignant fibrous his-
tiocytoma (10%), fibrosarcoma (7%), spindle cell sarcoma
(7%), myosarcoma (5%), undifferentiated sarcoma (2%)
and angiosarcoma (2%). Up to 41% of reported cases had
more than one type of sarcoma.3
Metastases are found in 25% to 64% of cases at diagno-
sis.2,6 A review of 41 cases2 of carcinosarcoma found the
lungs to be the most common site (43%) followed by bone
or spine (26%), lymph nodes (19%), liver (17%), brain
(10%), and 2% each of peritoneum, pancreas, spleen,
penis, kidney, retroperitoneal space, pleura, and adrenal
glands.
Radical surgery is recommended for carcinosarcoma due
to its malignant nature and poor prognosis; however,
radiation, chemotherapy, and hormonal therapy are also
utilized. Overall prognosis with any treatment is poor,
with a survival period of approximately 7 months, ranging
from 34 days to 5 years.2 The 3-year survival rate is
approximately 10%.6 No factor, including age, history of
radiation, or androgen deprivation therapy, histologic
subtype, percentage of necrosis, percentage of sarcoma,
sarcoma grade, or Gleason grade of adenocarcinoma, has
been found to be predictive of outcome.2,3
Robotic-assisted laparoscopic radical prostatectomy has
become widely adopted and robotic-assisted laparoscopic
cystoprostatectomy is now being developed in several
centers. Gill et al9 reported the initial two cases of lapa-
roscopic radical cystoprostatectomy with ileal conduit
performed completely intracorporeally in 2000. In 2003,
Menon et al10 reported a series of 17 robotic-assisted
radical cystoprostatectomies and urinary diversions for
bladder cancer focusing on nerve preservation. They used
a 3-step technique of robotic pelvic lymphadenectomy
and cystoprostatectomy followed by externalization of
bowel and extracorporeal neobladder reconstruction, and
internalization of the neobladder with robotic urethra-
vesical anastomosis. Balaji et al11 reported one case of
robotic-assisted radical cystoprostatectomy and ileal con-
duit urinary diversion performed totally intracorporeally.
Blood loss was 500mL, operative time 828 minutes, and
hospital stay 10 days. Concurrently, Yohannes et al12 re-
ported 2 cases of robotic-assisted radical cystoprostatec-
tomy with ileal conduit urinary diversion with intracorpo-
real ileal conduit construction. Estimated blood loss was
435mL and 1800mL, operative time 10 hours and 12 hours,
and hospital stay 6 days for both patients.
CONCLUSION
To date, all reported robotic-assisted cystoprostatectomies
have been performed for bladder cancer. We report the
first case of robotic-assisted radical cystoprostatectomy for
prostatic carcinosarcoma. Our acceptable operative time
and short convalescence suggest that the robotic interface
may facilitate minimally invasive cystoprostatectomy.
Larger studies are certainly needed to determine whether
robotic-assistance provides any advantages over standard
open surgery.
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